Study:
A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin
Rationale:
Amifostine may be an effective treatment for the toxic side effects caused by
radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation
therapy are more effective with or without amifostine for non-small cell lung cancer.
Purpose:
Randomized phase III trial to determine the effectiveness of amifostine in treating
patients who have stage II or stage III non-small cell lung cancer that cannot be surgically
removed and who are undergoing chemotherapy and radiation therapy.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer
Oral Complications
Radiation Toxicity |
Biological: filgrastim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: paclitaxel
Procedure: quality-of-life assessment
Radiation: radiation therapy |
Phase 3 |
Verified by
Radiation Therapy Oncology Group
November, 2010
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003313
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Supportive Care
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Benjamin Movsas, MD., Study Chair